Low Birth Weight, Preeclampsia (PE), Prevention &Amp; Control, Small for Gestational Age (SGA)
Conditions
Keywords
Aspirin, Preeclampsia, obstetric, risk population
Brief summary
Ρrееςlаmpѕia is a syndrome characterised by the new onset of hуреrtеnѕion plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation. It complicates 3-5% of pregnancies. Low-dose aspirin reduces the frequency of рrееςlampsia, as well as related adverse рrеgոaոcy outcomes (preterm birth, growth restriction), by 10 to 70% when taken by patients аt moderate to high risk of the disease. It has an excellent maternal/fetal safety profile. Thus, it is a reasonable preventive strategy for these patients. A pilot study at our hospital found that not all patients who are candidates for aspirin prescription receive it (only 40%). This audit cycle aims to increase aspirin prescription rates for moderate and high-risk obstetric populations.
Interventions
OTHERAspirin prescription on outpatient basis
Improving aspirin prescription rates for candidate patients (moderate- and high-risk obstetric population)
Sponsors
Cairo University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
Women at high risk are those with any of the following: 1. hypertensive disease during a previous pregnancy 2. chronic kidney disease 3. autoimmune disease such as systemic lupus erythematosus or antiphospholipid syndrome 4. type 1 or type 2 diabetes 5. chronic hypertension. Women with more than one moderate risk factor, such as are: 1. nulliparity 2. age 40 years or older 3. pregnancy interval of more than 10 years 4. body mass index (BMI) of 35 kg/m2 or more at first visit 5. family history of pre-eclampsia 6. multi-fetal pregnancy.
Exclusion criteria
* None. All eligible candidates will be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aspirin prescription | Six months |
Countries
Kuwait
Outcome results
None listed